In Canada, approximately 2200–2900 patients per year with stage II–III HER2+ breast cancer are referred for consideration of neoadjuvant trastuzumab plus chemotherapy which achieves higher pCR rates compared to chemotherapy alone [13]. This evidence concerns the gene ERBB2 and breast carcinoma.